Feasibility study of patient-specific quality assurance system for high-dose-rate brachytherapy in patients with cervical cancer

Boram Lee, Sung Hwan Ahn, Hyeyoung Kim, Youngyih Han, Seung Jae Huh, Jin Sung Kim, Dong Wook Kim, Jina Sim, Myonggeun Yoon

Research output: Contribution to journalArticle

Abstract

This study was conducted for the purpose of establishing a quality-assurance (QA) system for brachytherapy that can ensure patient-specific QA by enhancing dosimetric accuracy for the patient’s therapy plan. To measure the point-absorbed dose and the 2D dose distribution for the patient’s therapy plan, we fabricated a solid phantom that allowed for the insertion of an applicator for patient-specific QA and used an ion chamber and a film as measuring devices. The patient treatment plan was exported to the QA dose-calculation software, which calculated the time weight of dwell position stored in the plan DICOM (Digital Imaging and Communications in Medicine) file to obtain an overall beam quality correction factor, and that correction was applied to the dose calculations. Experiments were conducted after importing the patient’s treatment planning source data for the fabricated phantom and inserting the applicator, ion chamber, and film into the phantom. On completion of dose delivery, the doses to the ion chamber and film were checked against the corresponding treatment plan to evaluate the dosimetric accuracy. For experimental purposes, five treatment plans were randomly selected. The beam quality correction factors for ovoid and tandem brachytherapy applicators were found to be 1.15 and 1.10 − 1.12, respectively. The beam quality correction factor in tandem fluctuated by approximately 2%, depending on the changes in the dwell position. The doses measured by using the ion chamber showed differences ranging from −2.4% to 0.6%, compared to the planned doses. As for the film, the passing rate was 90% or higher when assessed using a gamma value of the local dose difference of 3% and a distance to agreement of 3 mm. The results show that the self-fabricated phantom was suitable for QA in clinical settings. The proposed patient-specific QA for the treatment planning is expected to contribute to reduce dosimetric errors in brachytherapy and, thus, to enhancing treatment accuracy.

Original languageEnglish
Pages (from-to)1029-1036
Number of pages8
JournalJournal of the Korean Physical Society
Volume68
Issue number8
DOIs
Publication statusPublished - 2016 Apr 1

Fingerprint

assurance
cancer
dosage
ionization chambers
dwell
planning
therapy
files
medicine
insertion
delivery
communication
computer programs

Keywords

  • Applicator
  • Brachytherapy
  • Patient-specific QA
  • Phantom

ASJC Scopus subject areas

  • Physics and Astronomy(all)

Cite this

Feasibility study of patient-specific quality assurance system for high-dose-rate brachytherapy in patients with cervical cancer. / Lee, Boram; Ahn, Sung Hwan; Kim, Hyeyoung; Han, Youngyih; Huh, Seung Jae; Kim, Jin Sung; Kim, Dong Wook; Sim, Jina; Yoon, Myonggeun.

In: Journal of the Korean Physical Society, Vol. 68, No. 8, 01.04.2016, p. 1029-1036.

Research output: Contribution to journalArticle

Lee, Boram ; Ahn, Sung Hwan ; Kim, Hyeyoung ; Han, Youngyih ; Huh, Seung Jae ; Kim, Jin Sung ; Kim, Dong Wook ; Sim, Jina ; Yoon, Myonggeun. / Feasibility study of patient-specific quality assurance system for high-dose-rate brachytherapy in patients with cervical cancer. In: Journal of the Korean Physical Society. 2016 ; Vol. 68, No. 8. pp. 1029-1036.
@article{441aba6b90be450d87939aa1bba14ac2,
title = "Feasibility study of patient-specific quality assurance system for high-dose-rate brachytherapy in patients with cervical cancer",
abstract = "This study was conducted for the purpose of establishing a quality-assurance (QA) system for brachytherapy that can ensure patient-specific QA by enhancing dosimetric accuracy for the patient’s therapy plan. To measure the point-absorbed dose and the 2D dose distribution for the patient’s therapy plan, we fabricated a solid phantom that allowed for the insertion of an applicator for patient-specific QA and used an ion chamber and a film as measuring devices. The patient treatment plan was exported to the QA dose-calculation software, which calculated the time weight of dwell position stored in the plan DICOM (Digital Imaging and Communications in Medicine) file to obtain an overall beam quality correction factor, and that correction was applied to the dose calculations. Experiments were conducted after importing the patient’s treatment planning source data for the fabricated phantom and inserting the applicator, ion chamber, and film into the phantom. On completion of dose delivery, the doses to the ion chamber and film were checked against the corresponding treatment plan to evaluate the dosimetric accuracy. For experimental purposes, five treatment plans were randomly selected. The beam quality correction factors for ovoid and tandem brachytherapy applicators were found to be 1.15 and 1.10 − 1.12, respectively. The beam quality correction factor in tandem fluctuated by approximately 2{\%}, depending on the changes in the dwell position. The doses measured by using the ion chamber showed differences ranging from −2.4{\%} to 0.6{\%}, compared to the planned doses. As for the film, the passing rate was 90{\%} or higher when assessed using a gamma value of the local dose difference of 3{\%} and a distance to agreement of 3 mm. The results show that the self-fabricated phantom was suitable for QA in clinical settings. The proposed patient-specific QA for the treatment planning is expected to contribute to reduce dosimetric errors in brachytherapy and, thus, to enhancing treatment accuracy.",
keywords = "Applicator, Brachytherapy, Patient-specific QA, Phantom",
author = "Boram Lee and Ahn, {Sung Hwan} and Hyeyoung Kim and Youngyih Han and Huh, {Seung Jae} and Kim, {Jin Sung} and Kim, {Dong Wook} and Jina Sim and Myonggeun Yoon",
year = "2016",
month = "4",
day = "1",
doi = "10.3938/jkps.68.1029",
language = "English",
volume = "68",
pages = "1029--1036",
journal = "Journal of the Korean Physical Society",
issn = "0374-4884",
publisher = "Korean Physical Society",
number = "8",

}

TY - JOUR

T1 - Feasibility study of patient-specific quality assurance system for high-dose-rate brachytherapy in patients with cervical cancer

AU - Lee, Boram

AU - Ahn, Sung Hwan

AU - Kim, Hyeyoung

AU - Han, Youngyih

AU - Huh, Seung Jae

AU - Kim, Jin Sung

AU - Kim, Dong Wook

AU - Sim, Jina

AU - Yoon, Myonggeun

PY - 2016/4/1

Y1 - 2016/4/1

N2 - This study was conducted for the purpose of establishing a quality-assurance (QA) system for brachytherapy that can ensure patient-specific QA by enhancing dosimetric accuracy for the patient’s therapy plan. To measure the point-absorbed dose and the 2D dose distribution for the patient’s therapy plan, we fabricated a solid phantom that allowed for the insertion of an applicator for patient-specific QA and used an ion chamber and a film as measuring devices. The patient treatment plan was exported to the QA dose-calculation software, which calculated the time weight of dwell position stored in the plan DICOM (Digital Imaging and Communications in Medicine) file to obtain an overall beam quality correction factor, and that correction was applied to the dose calculations. Experiments were conducted after importing the patient’s treatment planning source data for the fabricated phantom and inserting the applicator, ion chamber, and film into the phantom. On completion of dose delivery, the doses to the ion chamber and film were checked against the corresponding treatment plan to evaluate the dosimetric accuracy. For experimental purposes, five treatment plans were randomly selected. The beam quality correction factors for ovoid and tandem brachytherapy applicators were found to be 1.15 and 1.10 − 1.12, respectively. The beam quality correction factor in tandem fluctuated by approximately 2%, depending on the changes in the dwell position. The doses measured by using the ion chamber showed differences ranging from −2.4% to 0.6%, compared to the planned doses. As for the film, the passing rate was 90% or higher when assessed using a gamma value of the local dose difference of 3% and a distance to agreement of 3 mm. The results show that the self-fabricated phantom was suitable for QA in clinical settings. The proposed patient-specific QA for the treatment planning is expected to contribute to reduce dosimetric errors in brachytherapy and, thus, to enhancing treatment accuracy.

AB - This study was conducted for the purpose of establishing a quality-assurance (QA) system for brachytherapy that can ensure patient-specific QA by enhancing dosimetric accuracy for the patient’s therapy plan. To measure the point-absorbed dose and the 2D dose distribution for the patient’s therapy plan, we fabricated a solid phantom that allowed for the insertion of an applicator for patient-specific QA and used an ion chamber and a film as measuring devices. The patient treatment plan was exported to the QA dose-calculation software, which calculated the time weight of dwell position stored in the plan DICOM (Digital Imaging and Communications in Medicine) file to obtain an overall beam quality correction factor, and that correction was applied to the dose calculations. Experiments were conducted after importing the patient’s treatment planning source data for the fabricated phantom and inserting the applicator, ion chamber, and film into the phantom. On completion of dose delivery, the doses to the ion chamber and film were checked against the corresponding treatment plan to evaluate the dosimetric accuracy. For experimental purposes, five treatment plans were randomly selected. The beam quality correction factors for ovoid and tandem brachytherapy applicators were found to be 1.15 and 1.10 − 1.12, respectively. The beam quality correction factor in tandem fluctuated by approximately 2%, depending on the changes in the dwell position. The doses measured by using the ion chamber showed differences ranging from −2.4% to 0.6%, compared to the planned doses. As for the film, the passing rate was 90% or higher when assessed using a gamma value of the local dose difference of 3% and a distance to agreement of 3 mm. The results show that the self-fabricated phantom was suitable for QA in clinical settings. The proposed patient-specific QA for the treatment planning is expected to contribute to reduce dosimetric errors in brachytherapy and, thus, to enhancing treatment accuracy.

KW - Applicator

KW - Brachytherapy

KW - Patient-specific QA

KW - Phantom

UR - http://www.scopus.com/inward/record.url?scp=84964311344&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964311344&partnerID=8YFLogxK

U2 - 10.3938/jkps.68.1029

DO - 10.3938/jkps.68.1029

M3 - Article

VL - 68

SP - 1029

EP - 1036

JO - Journal of the Korean Physical Society

JF - Journal of the Korean Physical Society

SN - 0374-4884

IS - 8

ER -